Physician profile
Amber N Walker
NPI 1790468833
$4,254.12
in general payments reported to CMS, 2019-2025
21 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $771 · 2024: $1,278 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,198 · Education: $55.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,198.32 |
| Education | $55.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,110.01 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $944.81 | 2023-2025 | Airsupra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $429.05 | 2024-2025 | Dupixent |
| Insmed, INC. | $279.26 | 2023-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $226.60 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $216.75 | 2023-2025 | Winrevair |
| Grifols USA, LLC | $213.49 | 2023-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $154.23 | 2024-2025 | Glassia |
| Viatris Specialty LLC | $142.56 | 2025 | Yupelri |
| Mylan Specialty L.P. | $115.28 | 2023-2024 | Yupelri |
| Verona Pharma, INC. | $101.11 | 2025 | Ohtuvayre |
| Electromed, INC. | $84.70 | 2024-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.60 | 2023-2024 | Ofev |
| Vifor Pharma, INC. | $36.28 | 2024 | Zemaira, Veltassa |
| United Therapeutics Corporation | $28.27 | 2024 | Tyvaso |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $23.74 | 2024 | Sapien 3 Ultra Resilia |
| Amgen INC. | $22.15 | 2024 | Tezspire |
| Philips North America LLC | $22.13 | 2025 | Vest Therapy Und |
| Lilly USA, LLC | $20.99 | 2025 | Mounjaro |
| Baxter Healthcare | $20.79 | 2024 | Hillrom - Monarch Airway Clearance System |
| Paratek Pharmaceuticals, INC. | $19.32 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.